Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event

Clinical Genitourinary Cancer

Volumn 12, Issue 1, 2014, Pages

  Hahn, Noah M ^a   Yiannoutsos, Constantin T ^b   Kirkpatrick, Kristina ^c   Sharma, Jaya ^d   Sweeney, Christopher J ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hoosier Oncology Group   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Androgen deprivation therapy; Bone turnover; Prostate cancer; Skeletal related events

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTIANDROGEN; CALCIUM CARBONATE; DEOXYPYRIDINOLINE; GONADORELIN AGONIST; OSTEOCALCIN; PROSTATE SPECIFIC ANTIGEN; RISEDRONIC ACID; VITAMIN D;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; BONE TURNOVER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ENZYME BLOOD LEVEL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MIDDLE AGED; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; URINE LEVEL;

ANDROGEN DEPRIVATION THERAPY; BONE TURNOVER; PROSTATE CANCER; SKELETAL-RELATED EVENTS;

AGED; ALKALINE PHOSPHATASE; AMINO ACIDS; ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORCHIECTOMY; OSTEOCALCIN; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892442211     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.07.002     Document Type: Article

References (28)

1. R. Siegel, E. Ward, and O. Brawley et al. Cancer statistics, 2011:the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2012 212 236
2. R.E. Coleman Skeletal complications of malignancy Cancer 80 8 suppl 1997 1588 1594
3. H.W. Daniell, S.R. Dunn, and D.W. Ferguson et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 163 2000 181 186
4. K. Fizazi, M. Carducci, and M. Smith et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, double-blind study Lancet 377 2011 813 822
5. F. Saad, D.M. Gleason, and R. Murray et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
6. E.J. Small, M.R. Smith, and J.J. Seaman et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer J Clin Oncol 21 2003 4277 4284
7. D.P. Dearnaley, M.D. Mason, and M.K. Parmar et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials Lancet Oncol 10 2009 872 876
8. D.P. Dearnaley, M.R. Sydes, and M.D. Mason et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial) J Natl Cancer Inst 95) 2003 1300 1311
9. M.R. Smith, F.J. McGovern, and A.L. Zietman et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 2001 948 955
10. R.S. Israeli, S.J. Rosenberg, and D.R. Saltzstein et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy Clin Genitourin Cancer 5 2007 271 277
11. S.L. Greenspan, J.B. Nelson, and D.L. Trump et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial Ann Intern Med 146 2007 416 424
12. J.R. Green, K. Muller, and K.A. Jaeggi Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound J Bone Miner Res 9 1994 745 751
13. R.E. Coleman, P. Major, and A. Lipton et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid J Clin Oncol 23 2005 4925 4935
14. S. Rajpar, C. Massard, and A. Laplanche et al. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer Ann Oncol 21 2010 1864 1869
15. A. Lipton, R. Cook, and F. Saad et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Cancer 113 2008 193 201
16. C.J. Logothetis, E. Basch, and A. Molina et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Lancet Oncol 13 2012 1210 1217
17. H.I. Scher, S. Halabi, and I. Tannock et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
18. V. Paleri, and R.G. Wight Applicability of the adult comorbidity evaluation-27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study J Laryngol Otol 116 2002 200 205
19. D.P. Petrylak, C.M. Tangen, and M.H. Hussain et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
20. I.F. Tannock, R. de Wit, and W.R. Berry et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
21. J.S. de Bono, C.J. Logothetis, and A. Molina et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
22. J.S. de Bono, S. Oudard, and M. Ozguroglu et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
23. P.W. Kantoff, C.S. Higano, and N.D. Shore et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
24. K. Izumi, A. Mizokami, and S. Itai et al. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis BJU Int 109 2012 394 400
25. M.D. Michaelson, D.S. Kaufman, and H. Lee et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer J Clin Oncol 25 2007 1038 1042
26. C.W. Ryan, D. Huo, and L.M. Demers et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer J Urol 176 2006 972 978 discussion 978
27. F. Saad, D.M. Gleason, and R. Murray et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer [see comment] J Natl Cancer Inst 96 2004 879 882
28. M.R. Smith, J. Eastham, and D.M. Gleason et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012